Received Feb 4, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | LA |
Chills; Neurological symptom; Repetitive feeling of brain zap or jolt; Nausea; Fatigue; This non-serious case was reported by a consumer via sales rep and described the occurrence of chills in a female patient who received Herpes zoster (Shingrix) for prophylaxis. Concurrent medical conditions included migraine and hypertension. Concomitant products included amitriptyline hydrochloride (Amitriptyline), hydrochlorothiazide and verapamil hydrochloride (Verapamil). On 23-JAN-2026, the patient received Shingrix (left deltoid). In JAN-2026, less than a week after receiving Shingrix, the patient experienced brain zaps (Verbatim: Repetitive feeling of brain zap or jolt), nausea (Verbatim: Nausea) and fatigue (Verbatim: Fatigue). On 24-JAN-2026, the patient experienced chills (Verbatim: Chills) and neurological symptom (Verbatim: Neurological symptom). On 25-JAN-2026, the outcome of the chills and neurological symptom were resolved (duration 1 day). The outcome of the brain zaps, nausea and fatigue were not reported. It was unknown if the reporter considered the chills, neurological symptom, brain zaps, nausea and fatigue to be related to Shingrix. It was unknown if the company considered the chills, neurological symptom, brain zaps, nausea and fatigue to be related to Shingrix. Additional Information: GSK Receipt Date: 24-JAN-2026 It was reported as a subsequent dose. The batch number was not provided, and we are unable to contact the reporter.
Hypertension; Migraine
AMITRIPTYLINE; HYDROCHLOROTHIAZIDE; VERAPAMIL